Comera Life Sciences Holdings Inc CMRA shares are trading higher by 46.33% to $2.70 during Wednesday's after-hours session after the company announced it has entered into a purchase agreement with Arena Business Solutions for up to $15 million of the company's common stock.
"The line of credit provides the opportunity to invest in our pipeline and proprietary formulation platform, SQore™, which is designed to transform intravenous biologics into subcutaneous versions that patients can self-administer in a single dose," said Jeffrey Hackman, President, Chief Executive Officer and Chairman of Comera.
"Strengthening our balance sheet will help us achieve our strategic objectives in the near-term, and we are grateful for Arena's commitment to Comera's success," Hackman stated.
See Also: Why Novavax Shares Are Getting Hammered After Moderna, Pfizer And BioNTech News
According to data from Benzinga Pro, Comera Life Sciences has a 52-week high of $15.30 and a 52-week low of $1.11.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
